一美国人写的B题第二问答案（求助，用SAS做的，我看不懂！）

末代末

<p><u><font color="#800080"></font></u></p><p><u><font color="#800080"></font></u></p><u><font color="#800080"><p><br/>一美国人写的B题第二问答案（求助，用SAS做的，我看不懂！）</p><p>我贴在我的博客里了</p><p><a href="http://blog.sina.com.cn/u/1244765643">http://blog.sina.com.cn/u/1244765643</a></p><p>是从一个美国网站上找到的，真的看不懂，因为不会用SAS</p><p>另外，请看懂的或者看明白了的同仁能慷慨一下&nbsp; </p><p>与我联系联系 教教我&nbsp; </p><p>真的很急！！！</p><p>在这里先谢了！！<br/>S：本来前天就搜到了的 但是老师不让外传 但现在实在来不及了<br/>&nbsp;我们明天8点交卷 我现在在武汉</p><p>就算不行也希望和大家交个朋友<br/>下面是一些片段</p><p></p><p><br/>Repeated CD4 counts data from AIDS clinical trial.</p><p>Source: AIDS Clinical Trial Group 193A Study.&nbsp; <br/>Data courtesy of Dr. Keith Henry.</p><p>Reference: Henry, K., Erice, A., Tierney, C., Balfour, H.H. Jr, Fischl, M.A.,<br/>Kmack, A., Liou, S.H., Kenton, A., Hirsch, M.S., Phair, J., Martinez, A.&nbsp; <br/>and Kahn J.O. for the AIDS Clinical Trial Group 193A Study Team (1998).&nbsp; <br/>A randomized, controlled, double-blind study comparing the survival benefit of&nbsp; <br/>four different reverse transcriptase inhibitor therapies (three-drug, two-drug,<br/>and alternating drug) for the treatment of advanced AIDS. Journal of Acquired&nbsp; <br/>Immune Deficiency Syndromes and Human Retrovirology, 19, 339-349.</p><p><br/>Description:</p><p>The data are from a randomized, double-blind, study of AIDS patients with&nbsp; <br/>advanced immune suppression (CD4 counts of less than or equal to 50 cells/mm^3).<br/>atients in AIDS Clinical Trial Group (ACTG) Study 193A were randomized to&nbsp; <br/>dual or triple combinations of HIV-1 reverse transcriptase inhibitors.&nbsp; <br/>Specifically, patients were randomized to one of four daily regimens containing<br/>600mg of zidovudine: zidovudine alternating monthly with 400mg didanosine;<br/>zidovudine plus 2.25mg of zalcitabine; zidovudine plus 400mg of didanosine;&nbsp; <br/>or zidovudine plus 400mg of didanosine plus 400mg of nevirapine (triple therapy).&nbsp; <br/>Measurements of CD4 counts were scheduled to be collected at baseline and at&nbsp; <br/>8-week intervals during follow-up. However, the CD4 count data are unbalanced&nbsp; <br/>due to mistimed measurements and missing data that resulted from skipped visits<br/>and dropout. The number of measurements of CD4 counts during the first 40&nbsp; <br/>weeks of follow-up varied from 1 to 9, with a median of 4.&nbsp; <br/>The response variable is the log transformed CD4 counts, log(CD4 counts + 1),&nbsp; <br/>available on 1309 patients.<br/>The categorical variable Treatment is coded 1 = zidovudine alternating monthly&nbsp; <br/>with 400mg didanosine, 2 = zidovudine plus 2.25mg of zalcitabine, 3 = zidovudine<br/>plus 400mg of didanosine, and 4 = zidovudine plus 400mg of didanosine plus&nbsp; <br/>400mg of nevirapine. The variable Week represents time since baseline (in weeks).</p><p><br/>Variable List: Subject ID, Treatment, Age (years), Gender (1=M, 0=F), Week, log(CD4 count + 1).</p><p><br/>&nbsp;1 2 36.4271 1 0.0000 3.13549421590<br/>&nbsp;1 2 36.4271 1 7.5714 3.04452243770<br/>&nbsp;1 2 36.4271 1 15.5714 2.77258872220<br/>&nbsp;1 2 36.4271 1 23.5714 2.83321334410<br/>&nbsp;1 2 36.4271 1 32.5714 3.21887582490<br/>&nbsp;1 2 36.4271 1 40.0000 3.04452243770<br/>&nbsp;2 4 47.8467 1 0.0000 3.06805293510<br/>&nbsp;2 4 47.8467 1 8.0000 3.89182029810 <br/><a href="http://www.shumo.com/bbs/index.asp"></a></p></font></u><a href="http://www.shumo.com/bbs/index.asp"></a>